England R J A, Kamath M B, Jabreel A, Dunne G, Atkin S L
Departments of Otolaryngology Head and Neck Surgery and Endocrinology, Hull Royal Infirmary, UK.
Clin Otolaryngol. 2006 Apr;31(2):160-2. doi: 10.1111/j.1749-4486.2006.01150.x.
Radioiodine and thionamide treatment are the most frequently used treatment modalities for thyrotoxicosis in Europe and North America with surgery being reserved for selected cases. * In our clinic patients were offered all three modalities via simultaneous interview with an endocrinologist and a surgeon, with international risk benefit data for radioiodine and thionamide therapy, and local risk benefit data for total thyroidectomy provided. * When given the choice, at least 15% of patients opted for total thyroidectomy over the other modalities. * In our series of 100 consecutive surgical patients there was a 4% malignancy rate. * Total thyroidectomy should be offered equally, with radioiodine and thionamide treatment, as a first line treatment modality in the management of thyrotoxicosis.
在欧洲和北美,放射性碘和硫酰胺类药物治疗是甲状腺毒症最常用的治疗方式,手术则用于特定病例。在我们的诊所,通过同时与内分泌科医生和外科医生面谈,为患者提供了所有三种治疗方式,并提供了放射性碘和硫酰胺类药物治疗的国际风险效益数据以及甲状腺全切除术的本地风险效益数据。当有选择时,至少15%的患者选择甲状腺全切除术而非其他治疗方式。在我们连续的100例手术患者系列中,恶性肿瘤发生率为4%。甲状腺全切除术应与放射性碘和硫酰胺类药物治疗一样,作为甲状腺毒症管理的一线治疗方式平等提供。